Innate Pharma (IPHA)

Executive Summary

Innate Pharma is a clinical-stage oncology-focused biotechnology company based in Marseille, France, specializing in therapeutic antibodies that harness the innate immune system. The company's pipeline includes several novel candidates targeting NK cell checkpoints and other immune pathways. Key assets include IPH5201 (anti-CD39), which is in a Phase 2 trial for non-small cell lung cancer (NSCLC) in combination with durvalumab and chemotherapy, with completion expected in September 2026. IPH4102 (anti-KIR3DL2) is being evaluated in a Phase 2 study for T-cell lymphoma, with final data collection scheduled for January 2026. Additionally, IPH4502 (Nectin-4 targeting ADC) and IPH6501 (CD20-targeted NK cell engager) are in early-stage trials for solid tumors and non-Hodgkin lymphoma, respectively. The company has a broad IP portfolio and partnerships, including a collaboration with AstraZeneca on monalizumab (anti-NKG2A), though monalizumab's CLL trial was terminated. Innate remains a high-risk, high-reward play in immuno-oncology, with upcoming data readouts that could significantly impact its valuation. Conviction is tempered by early-stage data and competitive landscape.

Upcoming Catalysts (preview)

• Q4 2026IPH5201 Phase 2 topline data in NSCLC45% success
• Q2 2026IPH4102 Phase 2 final results in T-cell lymphoma50% success
• H2 2026IPH6501 Phase 1/2 initial efficacy data in NHL40% success